







FIG. 1






BEST AVAILABLE COPY

Inventor(s): Prusiner et al.
Title Cyclic Bis-Compounds Clearing
Malformed Proteins
Serial No.: To Be Assigned
Filing Date: Herewith (Nov. 25, 2003)
Attorney Docket: UCAL-243

3
FIG.




BEST AVAILABLE COPY

Inventor(s): Prusiner et al.
Title Cyclic Bis-Compounds Clearing
Malformed Proteins
Serial No.: To Be Assigned
Filing Date: Herewith (Nov. 25, 2003)
Attorney Docket: UCAL-243

FIG. 4



Quinacrine treatment 6 days [μ M] Followup 3 weeks after discontinuation



BEST AVAILABLE COPY

Inventor(s): Prusiner et al.
Title Cyclic Bis-Compounds Clearing
Malformed Proteins
Serial No.: To Be Assigned
Filing Date: Herewith (Nov. 25, 2003)
Attorney Docket: UCAL-243

PrPSc formation in ScN2a cells treated with (+)- and (-)-Quinacrine



BEST AVAILABLE COPY

Inventor(s): Prusiner et al.
Title Cyclic Bis-Compounds Clearing
Malformed Proteins
Serial No.: To Be Assigned
Filing Date: Herewith (Nov. 25, 2003)
Attorney Docket: UCAL-243




FIG. 6

Inventor(s): Prusiner et al.
Title Cyclic Bis-Compounds Clearing
Malformed Proteins
Serial No.: To Be Assigned
Filing Date: Herewith (Nov. 25, 2003)
Attorney Docket: UCAL-243




FIG. 7A

FIG. 7B

FIG. 7C

Inventor(s): Prusiner et al.
Title Cyclic Bis-Compounds Clearing
Malformed Proteins
Serial No.: To Be Assigned
Filing Date: Herewith (Nov. 25, 2003)
Attorney Docket: UCAL-243




FIG. 8A




FIG. 8B




FIG. 8C

Inventor(s): Prusiner et al.
Title Cyclic Bis-Compounds Clearing
Malformed Proteins
Serial No.: To Be Assigned
Filing Date: Herewith (Nov. 25, 2003)
Attorney Docket: UCAL-243




FIG. 9A




FIG. 9B

BEST AVAILABLE COPY